Boston Pharma

News

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

Cyberattack by an Iranian group against Stryker points to a shift in strategy from extortive to destructive assaults, as geopolitical conflicts rise.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.